Why the study?
Does fixed-dose combination therapy (amlodipine/benazepril) improve blood pressure reduction compared to high-dose monotherapy in high-risk patients with Stage 2 hypertension?
Does fixed-dose combination therapy (amlodipine/benazepril) improve blood pressure reduction compared to high-dose monotherapy in high-risk patients with Stage 2 hypertension?
Initial combination therapy for Stage 2 hypertension provides superior blood pressure reduction and potentially fewer adverse effects compared to high-dose monotherapy, supporting current guideline recommendations.
Answers are grounded in this paper and cite their sources.
May support initial fixed-dose combination over high-dose monotherapy in Stage 2 hypertension; leaves open prospective randomized confirmation.
Recent hypertension guidelines recommend initiating antihypertensive therapy with a combination of two or more agents in patients whose blood pressure exceeds their appropriate blood pressure goal by 20/10 mm Hg. This recommendation is based on the knowledge that the majority of patients with blood pressures of this magnitude will not achieve sufficient blood pressure reduction with monotherapy. Further, compared with high-dose monotherapy, combination therapy is often associated with fewer adverse effects and, for this reason, may improve patient adherence. Bringing patients to blood pressure goal quickly is likely to improve clinical outcomes. This article discusses the rationale for using combination antihypertensive therapy as initial therapy for high blood pressure in selected patients and reviews data from a study of 364 high-risk patients with Stage 2 hypertension in which a fixed-dose combination product (amlodipine besylate/benazepril HCl) proved more successful as initial therapy than high-dose monotherapy (amlodipine besylate) in reducing blood pressure.
No takes yet. Share an insight, caveat, or question.
Thomas D. Giles (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: